24 articles
Aclarubicin
Aclarubicin (aclacinomycin A), an anthracycline antineoplastic antibiotic from Streptomyces galilaeus isolated in 1975, inhibits topoisomerases I and II; used in AML induction, with lower cardiotoxicity than doxorubicin.
Aldoxorubicin
Aldoxorubicin (INNO-206) is an albumin-binding prodrug of doxorubicin using an acid-sensitive EMCH hydrazone linker, developed for soft-tissue sarcoma; phase 2b showed PFS benefit over doxorubicin, phase 3 did not.
Amrubicin
Amrubicin (Calsed, SM-5887), a synthetic 9-aminoanthracycline topoisomerase II inhibitor approved in Japan in 2002, is second-line therapy for relapsed small-cell lung cancer, with higher response rates than topotecan and hematologic toxicity as its main adverse effect.
AT regimen (chemotherapy)
The AT regimen is a combination chemotherapy of doxorubicin plus a taxane, docetaxel or paclitaxel, given on the same day, mainly to treat breast cancer.
Bisantrene
Bisantrene (Zantrene, CL-216942, NSC 337766) is an anthracenyl bishydrazone DNA-intercalating, topoisomerase II-inhibiting anticancer drug with doxorubicin-like activity but low cardiotoxicity, developed in the 1980s and rediscovered as an FTO inhibitor for AML.
Cabazitaxel
Cabazitaxel (Jevtana, XRP6258) is a Sanofi taxane microtubule inhibitor approved by the FDA in June 2010 with prednisone for metastatic castration-resistant prostate cancer after docetaxel, based on the TROPIC trial.
Capecitabine and paclitaxel regimen
The capecitabine and paclitaxel regimen is a combination chemotherapy doublet pairing oral capecitabine, a fluoropyrimidine prodrug, with intravenous paclitaxel, a taxane, given in 21-day cycles for metastatic breast and advanced gastric cancer.
Cyclophosphamide/doxorubicin regimen (chemotherapy)
The cyclophosphamide/doxorubicin regimen, usually abbreviated AC or CA, is a two-drug chemotherapy combination pairing the alkylator cyclophosphamide with the anthracycline doxorubicin, used mainly to treat operable breast cancer.
Docetaxel regimen
A docetaxel regimen is a chemotherapy protocol built around docetaxel, a taxane given intravenously, alone or with partners such as prednisone, to treat breast, lung, prostate, and other cancers.
Docetaxel/gemcitabine regimen
The docetaxel/gemcitabine regimen, also called docetaxel and gemcitabine, is a doublet chemotherapy combination pairing a taxane with an antimetabolite, best documented for soft-tissue sarcoma, especially leiomyosarcoma.
Dose-dense AC regimen
Dose-dense AC is an adjuvant breast cancer chemotherapy regimen giving doxorubicin and cyclophosphamide every 14 days for four cycles with mandatory G-CSF support, shown by trials to reduce recurrences.
Doxorubicin/gemcitabine regimen
The doxorubicin/gemcitabine regimen is a combination chemotherapy schedule pairing doxorubicin, an anthracycline, with gemcitabine, tested in advanced soft tissue sarcoma and studied earlier in metastatic breast cancer.
EC regimen (chemotherapy)
The EC regimen is a two-drug chemotherapy combination of epirubicin and cyclophosphamide, used mainly as neoadjuvant or adjuvant treatment for breast cancer over 3 to 6 cycles.
Eribulin
Eribulin (Halaven, eribulin mesylate) is a synthetic halichondrin B analogue microtubule inhibitor chemotherapy. FDA-approved 2010 for pretreated metastatic breast cancer and liposarcoma; EMBRACE trial showed 13.1 vs 10.6 months median survival.
Larotaxel
Larotaxel (RPR 109881, XRP9881), a Sanofi semi-synthetic taxane from 10-deacetylbaccatin III, stabilizes microtubules, is a poor P-glycoprotein substrate, crosses the blood-brain barrier, and was discontinued after phase III trials without market approval.
Nab-paclitaxel regimen
Nab-paclitaxel is a chemotherapy regimen of paclitaxel bound to albumin nanoparticles, FDA approved in 2005 for metastatic breast cancer and later for lung and pancreatic cancer.
Paclitaxel chemotherapy
Paclitaxel chemotherapy is cancer treatment with paclitaxel, a taxane drug originally isolated from the Pacific yew tree, FDA-approved in 1992 and used mainly for ovarian, breast, and lung cancers.
Paclitaxel poliglumex
Paclitaxel poliglumex (PPX, CT-2103, Xyotax, Opaxio) is an investigational water-soluble conjugate of paclitaxel with poly-L-glutamic acid, inactive until cathepsin B releases the drug in tumors; phase III NSCLC trials showed no survival advantage and its EMA application was withdrawn in 2009.
Paclitaxel regimen
A paclitaxel regimen is a chemotherapy treatment plan built around paclitaxel, a microtubule-stabilizing taxane given alone or combined with agents such as carboplatin, gemcitabine, or trastuzumab to treat ovarian, breast, lung, and pancreatic cancers.
Paclitaxel/topotecan regimen
The paclitaxel/topotecan regimen is an intravenous chemotherapy combination pairing the taxane paclitaxel with topotecan, developed for recurrent, persistent, and metastatic cervical cancer and studied in ovarian and breast tumors.
Pirarubicin
Pirarubicin (THP, 4'-O-tetrahydropyranyl doxorubicin, Pinorubicin) is a second-generation anthracycline chemotherapy drug developed in 1979, less cardiotoxic than doxorubicin, used in Japan for lymphoma, breast, gastric, and urothelial cancers.
Tesetaxel
Tesetaxel (DJ-927) is an oral semi-synthetic taxane chemotherapy candidate that stabilizes microtubules and evades P-glycoprotein resistance; its CONTESSA phase 3 breast cancer trial met its endpoint, but development was discontinued in 2021 after FDA feedback.
Utidelone
Utidelone (优替德隆, UTD1), an epothilone analogue microtubule stabilizer by Beijing Biostar, approved in China March 2021 with capecitabine for metastatic breast cancer; phase III PFS 8.44 vs 4.27 months, main toxicity peripheral neuropathy.
Valrubicin
Valrubicin (Valstar, AD 32) is a semisynthetic doxorubicin-analog anthracycline given intravesically at 800 mg weekly for six weeks for BCG-refractory bladder carcinoma in situ; FDA-approved September 25, 1998, withdrawn 2002, reintroduced 2009.